Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models
Por:
Gallego-Durán R., Álvarez-Amor L., Gil-Gómez A., Rojas Á., Muñoz-Hernández R., Cádernas-García A., Maya-Miles D., Montero-Vallejo R., Gato S., Sánchez Torrijos Y., Ampuero J., Martín F., Romero-Gómez M.
Publicada:
1 ene 2019
Resumen:
INTRODUCTION: non-alcoholic fatty liver disease is one of the most prevalent liver disorders in the developed world. Currently, there is no approved pharmacological therapy except for lifestyle intervention. Therefore, there is a need to increase the knowledge of preclinical models in order to boost novel discoveries that could lead to a better therapeutic management. MATERIAL AND METHODS: this study characterized the effects of two different diets, a long-term high-fat high-fructose diet (HF-HFD) and a choline-deficient, methionine supplemented high-fat diet (CDA-HFD) in C57BL/6J mice for 52 weeks or 16 weeks, respectively. Body weight, lipid and hepatic profile were analyzed and liver histology was subsequently evaluated. RESULTS: HF-HFD animals had an increased body weight and total cholesterol levels, whereas the opposite occurred in CDA-HFD. Both HF-HFD and CDA-HFD animals had higher ALT and AST levels. With regard to histology findings, HF-HFD and CDA-HFD diets induced an increased collagen deposit and intrahepatic steatosis accumulation. CONCLUSION: in conclusion, the comparison of these models aided in the selection of a long-term, more physiological model for physiopathology studies or a more rapid NASH model for novel molecule testing.
Filiaciones:
Gallego-Durán R.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group, Spain
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Álvarez-Amor L.:
CIBERDEM, Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad Pablo Olavide, Spain
Gil-Gómez A.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group, Spain
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Rojas Á.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Muñoz-Hernández R.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Cádernas-García A.:
CABIMER, Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad Pablo Olavide, Spain
Maya-Miles D.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Montero-Vallejo R.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Gato S.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Sánchez Torrijos Y.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group, Spain
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Ampuero J.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group, Spain
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
Martín F.:
CIBERDEM, Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad Pablo Olavide, Spain
Romero-Gómez M.:
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group
|